Legend Biotech Corp - Asset Resilience Ratio
Legend Biotech Corp (LEGN) has an Asset Resilience Ratio of 16.66% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See LEGN current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Legend Biotech Corp's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see LEGN asset base.
Liquid Assets Composition Over Time
This chart breaks down Legend Biotech Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore LEGN long-term investments to assets to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $291.71 Million | 16.66% |
| Total Liquid Assets | $291.71 Million | 16.66% |
Asset Resilience Insights
- Good Liquidity Position: Legend Biotech Corp maintains a healthy 16.66% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Legend Biotech Corp Industry Peers by Asset Resilience Ratio
Compare Legend Biotech Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Legend Biotech Corp (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Legend Biotech Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.69% | $46.70 Million | $1.73 Billion | -47.36pp |
| 2024-12-31 | 50.05% | $835.93 Million | $1.67 Billion | +48.37pp |
| 2023-12-31 | 1.68% | $31.00 Million | $1.85 Billion | -16.33pp |
| 2022-12-31 | 18.00% | $239.62 Million | $1.33 Billion | +0.72pp |
| 2021-12-31 | 17.28% | $193.46 Million | $1.12 Billion | +10.36pp |
| 2020-12-31 | 6.92% | $50.00 Million | $722.09 Million | -19.34pp |
| 2019-12-31 | 26.26% | $75.56 Million | $287.71 Million | +24.86pp |
| 2018-12-31 | 1.40% | $6.01 Million | $429.05 Million | -- |
About Legend Biotech Corp
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of mult… Read more